<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01826812</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00082755</org_study_id>
    <nct_id>NCT01826812</nct_id>
  </id_info>
  <brief_title>Impairment of Reading Ability in Dry Eye Patients</brief_title>
  <official_title>Functional Impairment of Reading Ability in Dry Eye Patients and Effects of Sustained Reading on the Ocular Surface</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the reading function impairment in patients with dry eye and to assess the effects
      of reading on the ocular surface.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being done to understand how reading is affected in people with dry eye in
      comparison with healthy controls and what effect reading has on the ocular surface in
      patients with dry eye.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Silent Reading Speed</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Total Ocular Staining Score (OSS)</measure>
    <time_frame>Before and after 30 minutes reading</time_frame>
    <description>Ocular staining score (OSS) is sum of the corneal and conjuctival staining scores with a total possible maximum score of 12 for each eye. Corneal staining is graded with a maximum possible fluorescein score of 6 for each cornea (the punctate epithelial erosions grade between 0-3 plus any extra points for modifiers up to 3). Nasal and temporal conjunctiva are graded separately with a score range between 0 and 3 for each area after instillation of lissamine green. An abnormal OSS is defined as being a total score of 3 or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tear Osmolarity</measure>
    <time_frame>Before and after 30 minutes reading</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Acuity</measure>
    <time_frame>30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines</measure>
    <time_frame>Tear samples were collected on the day of the exam. The samples were frozen to be assayed upon completion of the study.</time_frame>
    <description>Identification of various inflammatory cytokines in tear film of dry eye patients comparing to controls.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Dry Eye</arm_group_label>
    <description>The patients with Sjogren Syndrome related or non-Sjogren Syndrome related dry eye. The participants will be asked some questions. Before and after reading a text silently in 30 minutes &quot;30 minutes sustained reading&quot;, a detailed dry eye exam will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>The patients without dry eye. The participants will be asked some questions. Before and after reading a text silently in 30 minutes &quot;30 minutes sustained reading&quot;, a detailed dry eye exam will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>30 minutes sustained reading</intervention_name>
    <description>The participants will be given a text to read silently in 30 minutes.</description>
    <arm_group_label>Dry Eye</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dry eye exam</intervention_name>
    <description>Tear break-up time, tear collection, osmolarity, Schirmer test, corneal and conjunctival staining.</description>
    <arm_group_label>Dry Eye</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tears
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with known dry eye as well as normal healthy control subjects with no ocular
        surface diseases will be recruited from the Ocular Surface Diseases and Dry Eye Clinic as
        well as Glaucoma Clinic of the Wilmer Eye Institute.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age of 50 or greater,

          -  literacy in English language,

          -  ability to give informed consent

        Exclusion Criteria:

          -  binocular vision below 20/25,

          -  any ocular surgery within the last 3 months,

          -  mental issues,

          -  illiteracy,

          -  language problems which might possibly interfere with reading ability,

          -  history of taking or current use of topical prescription anti-inflammatory eye drops
             (including, cyclosporine and steroids as well as any glaucoma eye drops).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esen K Akpek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Wilmer Eye Institute, Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2013</study_first_submitted>
  <study_first_submitted_qc>April 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2013</study_first_posted>
  <results_first_submitted>January 12, 2016</results_first_submitted>
  <results_first_submitted_qc>February 24, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 24, 2016</results_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Ocular staining score (OSS) is sum of the corneal and conjuctival staining scores with a total possible maximum score of 12 for each eye. Corneal staining is graded with a maximum possible fluorescein score of 6 for each eye. Nasal and temporal conjunctiva are graded separately with a lissamine green staining score between 0 and 3 for each area.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dry Eye</title>
          <description>Dry eye defined as OSDI score more than 12 and/or total OSS score 3 and more</description>
        </group>
        <group group_id="P2">
          <title>Controls</title>
          <description>Controls defined as OSDI 12 and less AND total OSS score less than 3</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dry Eye</title>
          <description>Dry eye defined as OSDI score more than 12 and/or total OSS score 3 and more</description>
        </group>
        <group group_id="B2">
          <title>Controls</title>
          <description>Controls defined as OSDI 12 and less AND total OSS score less than 3</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="167"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.1" spread="8.7"/>
                    <measurement group_id="B2" value="61.4" spread="8.7"/>
                    <measurement group_id="B3" value="63.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Visual Acuity, logMAR</title>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.04" spread="0.11"/>
                    <measurement group_id="B2" value="-0.03" spread="0.10"/>
                    <measurement group_id="B3" value="-0.038" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Osmolarity</title>
          <units>mOsm/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="312" spread="28"/>
                    <measurement group_id="B2" value="306" spread="10"/>
                    <measurement group_id="B3" value="311" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline total OSS score</title>
          <description>Ocular staining score (OSS) is sum of the corneal and conjuctival staining scores with a total possible maximum score of 12 for each eye. Corneal staining is graded with a maximum possible fluorescein score of 6 for each eye (the punctate epithelial erosions grade between 0-3 plus any extra points for modifiers up to 3). Nasal and temporal conjunctiva are graded separately with a score range between 0 and 3 for each area after instillation of lissamine green. An abnormal OSS is defined as being a total score of 3 or more.</description>
          <units>scores on a scale of 0 to 12</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="3.3"/>
                    <measurement group_id="B2" value="0.9" spread="0.9"/>
                    <measurement group_id="B3" value="4.3" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sustained Silent Reading Speed</title>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dry Eye</title>
            <description>Dry eye defined as OSDI score more than 12 and/or total OSS score 3 and more</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>Controls defined as OSDI 12 and less AND total OSS score less than 3</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Silent Reading Speed</title>
          <units>words/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248.4" spread="79.5"/>
                    <measurement group_id="O2" value="270.3" spread="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Ocular Staining Score (OSS)</title>
        <description>Ocular staining score (OSS) is sum of the corneal and conjuctival staining scores with a total possible maximum score of 12 for each eye. Corneal staining is graded with a maximum possible fluorescein score of 6 for each cornea (the punctate epithelial erosions grade between 0-3 plus any extra points for modifiers up to 3). Nasal and temporal conjunctiva are graded separately with a score range between 0 and 3 for each area after instillation of lissamine green. An abnormal OSS is defined as being a total score of 3 or more.</description>
        <time_frame>Before and after 30 minutes reading</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dry Eye</title>
            <description>Dry eye defined as OSDI score more than 12 and/or total OSS score 3 and more</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>Controls defined as OSDI 12 and less AND total OSS score less than 3</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Ocular Staining Score (OSS)</title>
          <description>Ocular staining score (OSS) is sum of the corneal and conjuctival staining scores with a total possible maximum score of 12 for each eye. Corneal staining is graded with a maximum possible fluorescein score of 6 for each cornea (the punctate epithelial erosions grade between 0-3 plus any extra points for modifiers up to 3). Nasal and temporal conjunctiva are graded separately with a score range between 0 and 3 for each area after instillation of lissamine green. An abnormal OSS is defined as being a total score of 3 or more.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.4"/>
                    <measurement group_id="O2" value="1.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tear Osmolarity</title>
        <time_frame>Before and after 30 minutes reading</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dry Eye</title>
            <description>Dry eye defined as OSDI score more than 12 and/or total OSS score 3 and more</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>Controls defined as OSDI 12 and less AND total OSS score less than 3</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tear Osmolarity</title>
          <units>mOsm/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="12.3"/>
                    <measurement group_id="O2" value="1.8" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Visual Acuity</title>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dry Eye</title>
            <description>Dry eye defined as OSDI score more than 12 and/or total OSS score 3 and more</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>Controls defined as OSDI 12 and less AND total OSS score less than 3</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Acuity</title>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.07"/>
                    <measurement group_id="O2" value="0.02" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cytokines</title>
        <description>Identification of various inflammatory cytokines in tear film of dry eye patients comparing to controls.</description>
        <time_frame>Tear samples were collected on the day of the exam. The samples were frozen to be assayed upon completion of the study.</time_frame>
        <population>The cytokine analysis was performed in the samples of selected participants based on their clinical signs and characteristics. The sample size of the groups was justified using the power analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Dry Eye</title>
            <description>Patients with Sjogren Syndrome related or non-Sjogren Syndrome related dry eye.</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>Participants without dry eye.</description>
          </group>
        </group_list>
        <measure>
          <title>Cytokines</title>
          <description>Identification of various inflammatory cytokines in tear film of dry eye patients comparing to controls.</description>
          <population>The cytokine analysis was performed in the samples of selected participants based on their clinical signs and characteristics. The sample size of the groups was justified using the power analysis.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IFNg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.79" spread="16.81"/>
                    <measurement group_id="O2" value="150.10" spread="30.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.16" spread="54.63"/>
                    <measurement group_id="O2" value="107.53" spread="25.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.78" spread="39.65"/>
                    <measurement group_id="O2" value="69.64" spread="13.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL17A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.08" spread="28.39"/>
                    <measurement group_id="O2" value="200.00" spread="41.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL1b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.40" spread="5.09"/>
                    <measurement group_id="O2" value="27.87" spread="6.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="903.91" spread="268.02"/>
                    <measurement group_id="O2" value="157.58" spread="32.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211.69" spread="30.37"/>
                    <measurement group_id="O2" value="304.29" spread="55.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL12p70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.89" spread="10.06"/>
                    <measurement group_id="O2" value="131.32" spread="28.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Started with the first patient enrollment on 8/7/2013 until the last patient enrollment on 11/5/2015.</time_frame>
      <desc>The oversight total number of participants at risk was 200. Serious or non-serious adverse events were collected/assessed, but none observed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dry Eye</title>
          <description>Dry eye defined as OSDI score more than 12 and/or total OSS score 3 and more</description>
        </group>
        <group group_id="E2">
          <title>Controls</title>
          <description>Controls defined as OSDI 12 and less AND total OSS score less than 3</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Esen K. Akpek</name_or_title>
      <organization>The Wilmer Eye Institute, Johns Hopkins</organization>
      <phone>410-955-5214</phone>
      <email>esakpek@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

